VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG: VX-222
DRUG: telaprevir
DRUG: ribavirin

Sponsor

Vertex Pharmaceuticals Incorporated